

## DISCLOSURE OF POTENTIAL CONFLICTS OF INTEREST

**Consultancies:** Rasha Abdelsalam (SIDP, FADIC); Katie Barber (Paratek, Tetrphase); Samuel L. Aitken (Merck, Sharpe & Dohme; Shionogi); James Lewis (Merck, Entasis, Tetrphase); Thomas P. Lodise, Jr. (Merck, Allergan, Melinta, Shionogi, Nabriva, Achaogen); Ryan Mynatt (Shionogi Inc.); Jason M. Pogue (Merck, Shionogi, Tetrphas, Nabriva, Medicine's Company, Melinta, Achaogen); Ryan K. Shields (Merck, Shionogi, The Medicines Company, Achaogen); Jamie L. Wagner (Cutis Pharma, Inc.); Eric R. Wenzler (GenMark Diagnostics, Shionogi);

**Stock Ownership:**

**Royalties:**

**Grants:** Samuel L. Aitken (Melinta); Thomas P. Lodise, Jr. (Merck); Twisha S. Patel (Merck); Jason M. Pogue (Merck); Ryan K. Shields (Accelerate, Allergan, Merck, Melinta, Shionogi, Achaogen, Venatorx, Roche); Jamie L. Wagner (Making a Difference in Infectious Diseases); Eric R. Wenzler (Shionogi, Daiichi Sankyo, CDC, Melinta Therapeutics, Merck, Paratek Pharmaceuticals, Cystic Fibrosis Foundation, Astellas Pharma);

**Honoraria:** Rasha Abdelsalam (FADIC); Katie Barber (Paratek); Julie Ann Justo (bioMérieux); Thomas P. Lodise, Jr. (Melinta, Achaogen); Ryan Mynatt (Allergan); Jason M. Pogue (Merck, Melinta); Eric R. Wenzler (Melinta Therapeutics, Astellas Pharma, Achaogen)

**Other:**

**Nothing to disclose:** Melody Berg, Monique Bidell, Andrea R. Chbeir, Wasim El Nekidy, Lynne C. Krop, Erin K. McCreary, Cynthia T. Nguyen, Nikolas J. Onufrak, Jessica K. Ortwine, Jesse D. Sutton, Stephen B. Vickery

**ROLE OF BPS:** The Board of Pharmacy Specialties (BPS) is an autonomous division of the American Pharmacists Association (APhA). To maintain its strict, independent standards for certification, BPS does NOT endorse or provide review information, preparatory courses, or study guides for Board Certification Examinations. The Board, through its specialty councils, is responsible for specialty examination content, administration, scoring, and all other aspects of its certification programs. BPS is totally separate and distinct from ACCP. IDSAP has been approved by BPS for use in BCIDP recertification. Information about the BPS recertification process is available [online](#).

Questions regarding BCIDP recertification should be directed to:

**[Board of Pharmacy Specialties](#)**

2215 Constitution Avenue NW  
Washington, DC 20037  
(202) 429-7591

# MDR Gram-Negative Infections I Panel

---

## Series Editors:

### Elizabeth S. Dodds Ashley, Pharm.D., MHS, BCPS

*Associate Professor of Medicine*  
Division of Infectious Diseases  
Duke University School of Medicine  
*Director of Operations*  
Duke Antimicrobial Stewardship  
Outreach Network (DASON)  
Durham, North Carolina

### Alan E. Gross, Pharm.D., BCPS, BCIDP

*Clinical Assistant Professor*  
Department of Pharmacy Practice  
University of Illinois at Chicago College of Pharmacy  
*Infectious Diseases Pharmacist*  
Hospital Pharmacy Services  
University of Illinois Hospital and Health Sciences System  
Chicago, Illinois

## Faculty Panel Chair:

### Jason M. Pogue, Pharm.D., BCPS, BCIDP

*Clinical Professor, Infectious Diseases*  
Department of Clinical Pharmacy  
University of Michigan College of Pharmacy  
Ann Arbor, Michigan

## PSEUDOMONAS AERUGINOSA

### Authors

#### Thomas P. Lodise, Jr., Pharm.D., Ph.D.

*Professor*  
Department of Pharmacy Practice  
Albany College of Pharmacy and Health Sciences  
Albany, New York

#### Monique R. Bidell, Pharm.D., BCPS

*Clinical Pharmacist, Infectious Diseases*  
Department of Pharmacy  
Massachusetts General Hospital  
Boston, Massachusetts

### Reviewers

#### James S. Lewis II, Pharm.D., FIDSA

*ID Pharmacy Supervisor*  
Department of Pharmacy and Infectious Diseases  
Oregon Health and Science University  
Portland, Oregon

#### Jamie L. Wagner, Pharm.D., BCPS

*Clinical Assistant Professor*  
Department of Pharmacy Practice  
University of Mississippi School of Pharmacy  
Jackson, Mississippi

#### Stephen B. Vickery, Pharm.D., BCPS

*Assistant Professor of Pharmacy*  
Wingate University School of Pharmacy  
Hendersonville, North Carolina

## OTHER NONFERMENTERS: ACINOBACTER AND STENOTROPHOMONAS

### Authors

#### Katie E. Barber, Pharm.D.

*Assistant Professor*  
Department of Pharmacy Practice  
University of Mississippi School of Pharmacy  
Jackson, Mississippi

#### Jessica K. Ortwine, Pharm.D., BCPS-AQ ID

*Clinical Pharmacy Specialist, Infectious Diseases*  
Department of Pharmacy  
Parkland Health & Hospital System  
Dallas, Texas

### Reviewers

#### Jesse D. Sutton, Pharm.D., BCPS

*Antimicrobial Stewardship Pharmacist*  
Department of Pharmacy  
Veterans Affairs Salt Lake City Healthcare System  
Salt Lake City, Utah

#### Lynne C. Krop, Pharm.D., BCPS-AQ ID

*Clinical Coordinator, Infectious Diseases Specialist*  
Department of Pharmacy  
Morton Plant Mease Health Care (BayCare Health System)  
Clearwater, Florida

The American College of Clinical Pharmacy and the authors thank the following individuals for their careful review of the MDR Gram-Negative Infections I chapters:

#### Ralph H. Raasch, Pharm.D., FCCP, BCPS

*Associate Professor of Pharmacy (retired)*  
Division of Practice Advancement and Clinical Education  
Eshelman School of Pharmacy  
The University of North Carolina at Chapel Hill  
Chapel Hill, North Carolina

# MDR Gram-Negative Infections II Panel

---

## Series Editors:

### Elizabeth S. Dodds Ashley, Pharm.D., MHS, BCPS

*Associate Professor of Medicine*  
Division of Infectious Diseases  
Duke University School of Medicine  
*Director of Operations*  
Duke Antimicrobial Stewardship  
Outreach Network (DASON)  
Durham, North Carolina

### Alan E. Gross, Pharm.D., BCPS, BCIDP

*Clinical Assistant Professor*  
Department of Pharmacy Practice  
University of Illinois at Chicago College of Pharmacy  
*Infectious Diseases Pharmacist*  
Hospital Pharmacy Services  
University of Illinois Hospital and Health Sciences System  
Chicago, Illinois

## Faculty Panel Chair:

### Jason M. Pogue, Pharm.D., BCPS, BCIDP

*Clinical Professor, Infectious Diseases*  
Department of Clinical Pharmacy  
University of Michigan College of Pharmacy  
Ann Arbor, Michigan

## OPTIMIZING EMPIRIC GRAM-NEGATIVE THERAPY

### Author

#### Eric R. Wenzler, Pharm.D., BCPS, BCIDP, AAHIVP

*Assistant Professor*  
*Clinical Pharmacist, Infectious Diseases*  
University of Illinois at Chicago  
Chicago, Illinois

### Reviewers

#### Julie Ann Justo, Pharm.D., MS, BCPS-AQ ID

*Clinical Associate Professor*  
Department of Clinical Pharmacy and Outcomes Sciences  
University of South Carolina College of Pharmacy  
*Infectious Diseases Clinical Pharmacy Specialist*  
Prisma Health Richland Hospital  
Columbia, South Carolina

#### Wasim S. El Nekidy, Pharm.D., BCPS, BCACP, BCIDP

*Senior Pharmacotherapy Specialist*  
Department of Pharmacy Services  
Cleveland Clinic Abu Dhabi  
Abu Dhabi, United Arab Emirates

## PK/PD FOR OPTIMIZING THERAPY

### Author

#### Nikolas J. Onufrak, Pharm.D.

*Associate Director, Pharmacometrics*  
Institute for Clinical Pharmacodynamics  
Schenectady, New York

### Reviewers

#### Ryan P. Mynatt, Pharm.D., BCPS-AQ ID

*Clinical Pharmacist, Infectious Diseases*  
Department of Pharmacy Services  
University of Kentucky Healthcare  
Lexington, Kentucky

#### Rasha Abdelsalam Elshenawy, B.Pharm,

#### M.Sc., BCPS-AQ ID, TQM, CPHQ

*Senior Clinical Infectious Disease Pharmacist*  
Former Tanta University Hospitals (Egypt)  
*Chief Executive Officer*  
*Director of Antimicrobial Stewardship School*  
FADIC (First Arabian Drug Information Centre)  
Watford, United Kingdom

The American College of Clinical Pharmacy and the authors thank the following individuals for their careful review of the MDR Gram-Negative Infections II chapters:

#### Lynn Kassel, Pharm.D., BCPS

*Associate Professor of Clinical Sciences*  
Department of Clinical Sciences  
Drake University College of Pharmacy & Health Sciences  
Des Moines, Iowa  
*Acute Care Pharmacist*  
MercyOne West Des Moines Hospital  
West Des Moines, Iowa

#### Marisel Segarra-Newnham, Pharm.D., MPH, FCCP,

#### BCPS, BCIDP

*Clinical Pharmacy Specialist, Infectious Diseases/HIV*  
*Antimicrobial Stewardship Program Pharmacy Director*  
Veterans Affairs Medical Center  
West Palm Beach, Florida  
*Clinical Assistant Professor of Pharmacy Practice*  
University of Florida College of Pharmacy  
Gainesville, Florida

#### Jennifer Le, Pharm.D., MAS, FCCP, FCSHP, FIDSA,

#### BCPS-AQ ID

*Professor of Clinical Pharmacy*  
Skaggs School of Pharmacy and Pharmaceutical Sciences  
University of California, San Diego  
La Jolla, California

# MDR Gram-Negative Infections III Panel

---

## Series Editors:

### Elizabeth S. Dodds Ashley, Pharm.D., MHS, BCPS

*Associate Professor of Medicine*  
Division of Infectious Diseases  
Duke University School of Medicine  
*Director of Operations*  
Duke Antimicrobial Stewardship  
Outreach Network (DASON)  
Durham, North Carolina

### Alan E. Gross, Pharm.D., BCPS, BCIDP

*Clinical Assistant Professor*  
Department of Pharmacy Practice  
University of Illinois at Chicago College of Pharmacy  
*Infectious Diseases Pharmacist*  
Hospital Pharmacy Services  
University of Illinois Hospital and Health Sciences System  
Chicago, Illinois

## Faculty Panel Chair:

### Jason M. Pogue, Pharm.D., BCPS, BCIDP

*Clinical Professor, Infectious Diseases*  
Department of Clinical Pharmacy  
University of Michigan College of Pharmacy  
Ann Arbor, Michigan

## ANTIBIOTIC RESISTANCE IN ENTEROBACTERIACEAE

### Authors

#### Erin K. McCreary, Pharm.D., BCPS, BCIDP

*Clinical Pharmacist, Infectious Diseases*  
University of Pittsburgh Medical Center  
Pittsburgh, Pennsylvania

#### Ryan K. Shields, Pharm.D., MS

*Associate Professor of Medicine*  
University of Pittsburgh  
*Co-Director, Antimicrobial Management Program*  
Department of Medicine  
University of Pittsburgh Medical Center  
Pittsburgh, Pennsylvania

### Reviewers

#### Samuel L. Aitken, Pharm.D., MPH, BCPS-AQ ID, BCIDP

*Clinical Pharmacy Specialist – Infectious Diseases*  
Division of Pharmacy  
University of Texas MD Anderson Cancer Center  
Houston, Texas

#### Melody L. Berg, Pharm.D., MPH, BCPS

*Senior Content Management Consultant,  
Embedded Clinical Content*  
Department of Clinical Effectiveness  
Wolters Kluwer  
Indianapolis, Indiana

## RECORDED WEBCAST: PIPERACILLIN/ TAZOBACTAM VS. CARBAPENEMS FOR ESBL-PRODUCING ENTEROBACTERIACEAE

### Author

#### Twisha S. Patel, Pharm.D., BCPS, BCIDP

*Clinical Pharmacist Specialist, Infectious Diseases*  
Department of Pharmacy Services  
Michigan Medicine  
Ann Arbor, Michigan

### Reviewers

#### Jason M. Pogue, Pharm.D., BCPS, BCIDP

*Clinical Professor, Infectious Diseases*  
Department of Clinical Pharmacy  
University of Michigan College of Pharmacy  
Ann Arbor, Michigan

#### Cynthia T. Nguyen, Pharm.D., BCPS-AQ ID

*Clinical Pharmacy Specialist, Infectious Diseases*  
Department of Pharmacy  
University of Chicago Medicine  
Chicago, Illinois

#### Andrea R. Chbeir, Pharm.D., BCPS

*Director of Clinical Services*  
Affinity Patient Coordination  
Springfield, Illinois

The American College of Clinical Pharmacy and the authors thank the following individuals for their careful review of the MDR Gram-Negative Infections III features:

#### Ralph H. Raasch, Pharm.D., FCCP, BCPS

*Associate Professor of Pharmacy (retired)*  
Division of Practice Advancement and Clinical Education  
Eshelman School of Pharmacy  
The University of North Carolina at Chapel Hill  
Chapel Hill, North Carolina

#### Marisel Segarra-Newnham, Pharm.D., MPH, FCCP, BCPS, BCIDP

*Clinical Pharmacy Specialist, Infectious Diseases/HIV  
Antimicrobial Stewardship Program Pharmacy Director*  
Veterans Affairs Medical Center  
West Palm Beach, Florida  
*Clinical Assistant Professor of Pharmacy Practice*  
University of Florida College of Pharmacy  
Gainesville, Florida